Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs

By Ivan Moreno · August 5, 2026, 3:14 PM EDT

A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight loss drugs...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Eli Lilly And Company v. Revive RX, LLC

Case Number

4:23-cv-03521

Court

Texas Southern

Nature of Suit

Personal Property: Other

Date Filed

September 19, 2023